Sign In
19 Apr 2016 14:00
EXOVA GROUP PLC
Notification of transactions of Directors and PDMRs
19 April 2016
On 18 April 2016, awards in the form of nil cost awards ("Awards") taking the form of a nil cost option or conditional award (as set out below) to acquire ordinary shares of 1 pence each ("Shares") in Exova Group plc (the "Company") were granted to certain persons discharging managerial responsibilities ("PDMRs") under the Exova Group plc Long Term Incentive Plan ("LTIP"), as set out in column 3 in the table below.
The number of Shares subject to the Awards has been determined by reference to the market value of a Share on 18 April 2016 (162 pence per Share). In addition, the Company has granted market value options under the company share option plan section of the LTIP ("CSOP Option") over the number of Shares set out in column 4 of the table below to Paul Barry, a PDMR. The exercise price of each CSOP Option is 162 pence per Share, and has also been determined by reference to the market value of a Share on 18 April 2016. The number of Shares that is capable of exercise under the nil cost option will be reduced by such number of Shares as has a market value (at the date of exercise of the CSOP Option) equal to the gain made on the exercise of the CSOP Option. Overall, the participant's pre-tax economic gain from the nil cost option is the same as if the CSOP Option was not in place.
1. Name | 2. Status | 3. Number of Shares under Nil Cost Option |
| |
Ian El-Mokadem | Director/PDMR | 425,000 | - | |
Philip Marshall | Director/PDMR | 200,617 | - | |
Paul Barry | PDMR | 160,493 | 18,518 | |
Gary Brimmage | PDMR | 190,689* | - | |
Matthew Davies | PDMR | 106,179 | - | |
John Willox | PDMR | 126,543 | - |
* Award granted in form of a conditional share award
The vesting of the Awards and the CSOP Options is subject to the satisfaction of a performance condition set by the Remuneration Committee of the Company. The Awards and CSOP Options will normally vest and become exercisable on the later of the third anniversary of grant and the assessment of the performance condition, subject to continued employment. A total amount of £1 is payable on the exercise of any nil cost option.
No consideration was paid for the grant of any of the above awards.
This notification is made in accordance with DTR 3.1.4
For and on behalf of Exova Group plc
Date: 19 April 2016
Neil MacLennan
General Counsel & Company SecretaryTelephone: 0131 333 8053
About Exova
Exova is one of the world's leading laboratory-based testing groups, trusted by organisations to test and advise on the safety, quality and performance of their products and operations. Headquartered in Edinburgh, UK, Exova operates 145 laboratories and offices in 32 countries and employs around 4,500 people throughout Europe, the Americas, the Middle East and Asia/Asia Pacific.
Exova's capabilities help to extend asset life, bring predictability to applications, and shorten the time to market for customers' products, processes and materials. With over 90 years' experience, Exova specialises in testing across a number of key sectors from health sciences to aerospace, transportation, oil and gas, fire and construction.
Follow the stocks
